Full View

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma

A Mulero‐Sánchez, CFA Ramirez… - Molecular …, 2023 - Wiley Online Library
Liver cancer is the fourth most common cause of cancer‐related death worldwide, with
hepatocellular carcinoma (HCC) being the main primary malignancy affecting the liver …
被引用次数：6 相关文章

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma

A Mulero-Sánchez, CFA Ramirez… - Molecular …, 2023 - pubmed.ncbi.nlm.nih.gov
Liver cancer is the fourth most common cause of cancer-related death worldwide, with
hepatocellular carcinoma (HCC) being the main primary malignancy affecting the liver …

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma

A Mulero-Sánchez, CFA Ramirez… - Molecular …, 2023 - search.proquest.com
Liver cancer is the fourth most common cause of cancer-related death worldwide, with
hepatocellular carcinoma (HCC) being the main primary malignancy affecting the liver …
[HTML] nih.gov

[HTML][HTML] Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma

A Mulero‐Sánchez, CFA Ramirez… - Molecular …, 2023 - ncbi.nlm.nih.gov
Liver cancer is the fourth most common cause of cancer‐related death worldwide, with
hepatocellular carcinoma (HCC) being the main primary malignancy affecting the liver …

[引用][C] Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma

A Mulero-Seanchez, CFA Ramirez… - Molecular …, 2023 - europepmc.org
Hepatocellular carcinoma (HCC) is the most common primary liver tumor [1–3]. The
incidence of this cancer is particularly high in Asia [4] and is rising in western countries …